Boston Scientific is capping off a busy week with a major buyout, entering a deal worth about $14.5 billion to acquire California-based Penumbra. The company started off the week presenting at the ...

Boston Scientific is acquiring Penumbra for $374/share in a mixed cash/stock deal, filling a key portfolio gap in mechanical thrombectomy. While the acquisition is initially dilutive and seemingly ...

Boston Scientific Corp. agreed to buy medical device maker Penumbra Inc. in a deal valued at more than $14 billion to expand in the treatment of blood clots and stroke. Boston Scientific said it will ...

Penumbra expected to generate $1.4 bln in 2025 sales; shares surge 12% Transaction values Penumbra at $374 per share, 19.3% premium to last close Penumbra CEO Adam Elsesser to join Boston Scientific's ...

Boston Scientific has agreed to buy thrombectomy company Penumbra for about $15 billion in cash and stock in a deal that bolsters its cardiovascular portfolio. Boston Scientific on Thursday said the ...

During Boston Scientific chief executive Mike Mahoney’s 13-year tenure, he has presided over more than 40 acquisitions so far. But this one is different, at least by size: Mahoney on Thursday unveiled ...

The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate ...

Boston Scientific (BSX) on Thursday announced a definitive agreement to acquire Penumbra (PEN) in a cash and stock transaction that values the Alameda-based heart device maker at ~$14.5B, including ...

Penumbra Inc. CEO Adam Elsesser said in a conference call Thursday that Penumbra and Boston Scientific Corp. "share similar cultures within our company and feel strongly that combining these strengths ...

Fintel reports that on January 16, 2026, Baird downgraded their outlook for Penumbra (NYSE:PEN) from Outperform to Neutral. Analyst Price Forecast Suggests 2.25% Downside As of January 14, 2026, the ...

Fintel reports that on January 16, 2026, Jefferies downgraded their outlook for Penumbra (NYSE:PEN) from Buy to Hold. Analyst Price Forecast Suggests 2.25% Downside As of January 14, 2026, the average ...